Clinical Trial Update: Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ADI-PEG 20 versus placebo in patients with high arginine levels and unresectable hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING